The abstract is read at the publisher; the summary is JClub's.
A harmonized atlas of 7,612 bulk breast cancer transcriptomes from 22 datasets resolves malignant transcriptional states, including stem-like and neuroendocrine-differentiated subtypes.
- Why it matters: Cross-study technical variability has limited large-scale transcriptome comparisons, leaving clinical subtype definitions and tumor-cell state mapping less reliable.
- What they did: The study adapts single-cell RNA sequencing analytical strategies to integrate bulk data, then assigns malignant states and links them to clinical behavior across identified subtypes.
- The result: Neuroendocrine-differentiated (NED) tumors show luminal and neuroendocrine features with poor prognosis after chemo-endocrine therapy, while HER2E KIS identifies responders to neoadjuvant HER2-targeted kinase inhibition.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.